Accessibility Menu

Kyntra Bio

(NASDAQ) KYNB

Current Price$6.92
Market Cap$28.22M
Since IPO (2014)-99%
5 Year-99%
1 Year+29%
1 Month-0%

Kyntra Bio Financials at a Glance

Market Cap

$28.22M

Revenue (TTM)

$7.44M

Net Income (TTM)

$163.62M

EPS (TTM)

$27.47

P/E Ratio

0.25

Dividend

$0.00

Beta (Volatility)

1.55 (High)

Price

$6.92

Volume

1,739.939

Open

$6.85

Previous Close

$6.97

Daily Range

$6.85 - $6.92

52-Week Range

$4.85 - $12.60

Estimated Earnings Date

Aug 10, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kyntra Bio

Industry

Biotechnology

Employees

34

CEO

Thane Wettig, MBA

Headquarters

San Francisco, CA 94133, US

KYNB Financials

Key Financial Metrics (TTM)

Gross Margin

45.11%

Operating Margin

-603.83%

Net Income Margin

2199.42%

Return on Equity

-234.28%

Return on Capital

-82.69%

Return on Assets

149.24%

Earnings Yield

4.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$28.22M

Shares Outstanding

4.05M

Volume

1.74K

Avg. Volume

19.14K

Financials (TTM)

Gross Profit

$3.36M

Operating Income

-$44.92M

EBITDA

-$56.06M

Operating Cash Flow

-$21.38M

Capital Expenditure

-$22.00K

Free Cash Flow

-$21.40M

Cash & ST Invst.

$87.24M

Total Debt

$19.25M

Kyntra Bio Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$3.74M

+36.5%

Gross Profit

-$368.00K

-117.0%

Gross Margin

-9.84%

N/A

Market Cap

$28.22M

N/A

Market Cap/Employee

$125.40K

N/A

Employees

225

N/A

Net Income

-$15.20M

-427.6%

EBITDA

-$12.70M

+10.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$87.24M

+159.6%

Total Debt

$19.25M

-73.8%

Accounts Receivable

$5.04M

+3328.6%

Inventory

$3.38M

+7.3%

Long Term Debt

$19.25M

-73.8%

Short Term Debt

$0.00

N/A

Return on Assets

1.49%

N/A

Return on Invested Capital

-55.11%

N/A

Free Cash Flow

-$13.89M

-613.8%

Operating Cash Flow

-$13.89M

-610.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALGSAligos Therapeutics, Inc.
$5.59-1.06%
CELUCelularity Inc.
$0.69-0.77%
PDSBPDS Biotechnology Corporation
$0.89-2.59%
TPSTTempest Therapeutics, Inc.
$1.26+0.40%

Trending Stocks

Symbol / CompanyPricePrice Chg
WENWendy's
$7.76+0.24%
NOKNokia
$14.05+0.03%
PLSMPulsenmore
$9.12+1.67%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.16-0.01%

Questions About KYNB

What is the current price of Kyntra Bio?

Kyntra Bio is trading at $6.91 per share.

What is the 52-week range for Kyntra Bio?

Over the past 52 weeks, Kyntra Bio has traded between $4.85 and $12.60.

How much debt does Kyntra Bio have?

As of the most recent reporting period, Kyntra Bio reported total debt of $19.25M.

How much cash does Kyntra Bio have on hand?

Kyntra Bio reported $37.00M in cash and cash equivalents in its most recent financial results.

What is Kyntra Bio’s dividend yield?

Kyntra Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.